Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Sells $456,617.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jazz Pharmaceuticals Stock Down 2.1 %

Jazz Pharmaceuticals stock opened at $121.65 on Friday. The stock has a market cap of $7.35 billion, a PE ratio of 17.13, a P/E/G ratio of 1.07 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock’s fifty day moving average is $112.22 and its two-hundred day moving average is $110.35. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Versant Capital Management Inc boosted its holdings in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $29,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 97 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter worth $33,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on JAZZ shares. Piper Sandler decreased their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Wells Fargo & Company reduced their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. TD Cowen dropped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.